CCC.JSE Cilo Cybin Holdings Ltd
- Market cap
- ZAC 418M
- P/E
- -
- P/B
- 6.67x
- ROE
- -382.8%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the fiscal year ending Mar 2026.
Is CCC.JSE undervalued?
Graham numberThe Graham number of Cilo Cybin Holdings Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cilo Cybin Holdings Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-382.8%), below 10%.
ROA 0/1
Return on assets (-280.8%) is below the industry median (3.7%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-38,112.4%) is below the industry median (24.7%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (8.0%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 2/2
Cash covers 8.6 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (6.7x) is above the industry median (2.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Cilo Cybin Holdings Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cilo Cybin Holdings Ltd
Cilo Cybin Holdings Limited manufactures and sells medical cannabis products in South Africa, Australia, and internationally. The company offers active pharmaceutical ingredients (API) products comprising tetrahydrocannabinol (THC) crude oils, THC distillates, and refined THCs; cannabidiol (CBD) isolate powders, CBD crystal resistant distillates (CRD), CBD crudes, CBD distillates, and CBD-V isolates; and minor cannabinoid products, such as CBN isolates, cannabigerol (CBG) is…
Full company profileCilo Cybin Holdings Ltd financial statements
Cilo Cybin Holdings Ltd annual financial statements (ZAR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 35.4M | 28.8M |
| Gross Profit | 0.00 | 0.00 | -359K | 8.99M |
| Operating Income | -538K | -563K | -5.10M | -21.0M |
| EBITDA | -540K | 501K | 90.1K | -235M |
| Net Income | -552K | 455K | -586K | -240M |
| EPS | -0.01 | 0.01 | -0.01 | -3.23 |
| Balance Sheet | ||||
| Total Assets | 77.2K | 63.3M | 62.8M | 85.4M |
| Total Liabilities | 619K | 11.2M | 5.43M | 22.7M |
| Shareholders' Equity | -542K | 52.1M | 57.3M | 62.6M |
| Cash & Short-term Investments | 77.2K | - | 58.3M | 48.2M |
| Total Debt | 302K | - | 3.94M | 5.02M |
| Cash Flow | ||||
| Operating Cash Flow | -223K | 632K | -2.08M | 3.75M |
| Capital Expenditure | 0.00 | 3.00 | 50.9K | 9.37M |
| Free Cash Flow | -223K | 632K | -2.13M | -5.62M |
| Ratios | ||||
| ROE | - | 0.9% | -1.0% | -382.8% |
| ROA | -714.7% | 0.7% | -0.9% | -280.8% |
| Net Profit Margin | - | - | -1.7% | -832.0% |
| Debt to Equity | - | - | 0.07x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cilo Cybin Holdings Ltd dividends
Cilo Cybin Holdings Ltd has not paid dividends in the last 5 fiscal years.
Who owns Cilo Cybin Holdings Ltd
- Insiders 24.42%
- Institutions 0.00%
- Public & others 75.58%
- Shares outstanding 230M
- Free float 198M
Cilo Cybin Holdings Ltd company profile
- Company name
- Cilo Cybin Holdings Ltd
- Ticker
- CCC.JSE
- Exchange
- Johannesburg Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 30
- Fiscal year end
- March
- Address
- The Point Office Park, Centurion, South Africa, 0157
- Phone
- 27 861 420 421
- Website
- cilocybin.com
About Cilo Cybin Holdings Ltd
Cilo Cybin Holdings Limited manufactures and sells medical cannabis products in South Africa, Australia, and internationally. The company offers active pharmaceutical ingredients (API) products comprising tetrahydrocannabinol (THC) crude oils, THC distillates, and refined THCs; cannabidiol (CBD) isolate powders, CBD crystal resistant distillates (CRD), CBD crudes, CBD distillates, and CBD-V isolates; and minor cannabinoid products, such as CBN isolates, cannabigerol (CBG) isolates, CBG CRD, CBC isolates, THCV resins, and botanical CBT distillates. It also provides contract manufacturing services for finished cannabinoid products, including oils and tinctures; vape formats; edibles; topicals, including creams, balms, lotions, and other formats; capsules; and secondary packaging, such as labels and batches. In addition, the company operates an online shop for its products. Further, it invests in the biotech, biohacking, and pharmaceutical businesses. Cilo Cybin Holdings Limited was founded in 2018 and is based in Centurion, South Africa.
Cilo Cybin Holdings Ltd management
2- Mr. Gabriel Christiaan TheronFounder, CEO & Executive Director · born 1981
- Ms. Jessica Moodley-TheronActing CFO & Financial Director and Executive Director · born 1982